Tovet (Emollient Formulation)
Payments companies reported to CMS as associated with Tovet (Emollient Formulation). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tovet (Emollient Formulation), per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tovet (Emollient Formulation)
These are the largest totals companies reported as associated with Tovet (Emollient Formulation). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jason Green | Fort Lauderdale, FL | Dermatology | $1,400.00 |
| Danilo Delcampo | Chicago, IL | Dermatology | $350.00 |
| Robert Debellevue | Kenner, LA | Dermatology | $350.00 |
| Daniel Groisser | Verona, NJ | Dermatology | $350.00 |
| Emily Burger | Wiggins, MS | Physician Assistant | $250.00 |
| Sharleen St Surin-Lord | Largo, MD | Procedural Dermatology | $72.08 |
| Blake Robbins | Longview, TX | Dermatology | $63.57 |
| Michael Sabol | Hickory, NC | Physician Assistant | $60.08 |
| Gabriel Martinez Diaz | Chicago, IL | Dermatology | $50.04 |
| Lacey Walls | Concord, NC | Dermatology | $44.29 |
Prescribed Tovet (Emollient Formulation)?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.